Whalesbook
Coral Laboratories Ltd. announced the completion of its General Pharmaceuticals Formulation (Ointment) unit expansion at its Dehradun plant, marking the commencement of commercial operations at the enhanced facility. The expansion significantly boosts the plant's annual ointment production capacity to 360,000 kgs.
This increased capacity is primarily intended to meet growing demand for Coral Laboratories' ointment products in both domestic and international markets. The expansion project, first approved by the company's Board of Directors on October 13, 2025, required an investment of approximately ₹30 crore. Funding was sourced through a mix of bank overdraft and internal accruals, fulfilling the objective to double the ointment manufacturing capacity.
With commercial operations now active, Coral Laboratories is poised to utilize its expanded manufacturing capabilities. The company anticipates this will lead to higher sales volumes, potentially strengthening its market share and enhancing revenue from its ointment product line. Investors will be keen to monitor the sales performance and revenue contribution from this upgraded unit.
In a separate development, investors may recall that Coral Laboratories paid a Rs. 45,000 fine to the BSE in December 2024 due to a delay in submitting its financial results. The company had been cautioned that repeated non-compliance with financial reporting deadlines could result in trading suspension.
Coral Laboratories operates within India's competitive pharmaceutical sector, facing competition from major players such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Aarti Drugs, Divi's Laboratories, and Laurus Labs, many of whom operate at a large scale with global reach.
Key metrics associated with this expansion include the new 360,000 kgs annual capacity and the ₹30 crore investment. Tracking market share gains and Coral Laboratories' ability to meet demand effectively will be crucial indicators of its future growth trajectory.